Sonoma Pharmaceuticals, Inc. (SNOA): Submission of Matters to a Vote of Security Holders
Sonoma Pharmaceuticals, Inc. (SNOA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. Our annual meeting of stockholders was held on September 16, 2026. Proxies were solicited pursuant to our definitive proxy statement filed on July 28, 2026 with the Securities and Exchange Commission under Section 14
How this was made
The 30-second read
Why it matters
The filing is a routine corporate governance update with no immediate financial impact.
Market read
Low relevance; the disclosure is a standard governance filing with no material effect on price.
What to watch
Potential hidden dissent among shareholders not reflected in the vote totals.
Background
Sonoma Pharmaceuticals filed a Form 8‑K to disclose the outcomes of its 2026 annual shareholder meeting, including director election and advisory compensation vote.
Ticker impact
SEC 8‑K reports the results of Sonoma Pharmaceuticals' annual shareholder meeting votes on director election, executive compensation, auditor ratification and proxy adjournment.
Minimal impact; price likely to remain unchanged.
Proxy results are routine disclosures with no new financial or strategic information that would move the stock.
Market effects
None; governance update does not affect the biotech sector broadly.
None; limited to the company.
None
Counterpoint
If activist investors target the board, future proxy battles could become material.
Key entities
- companySonoma Pharmaceuticals, Inc.
Biopharmaceutical company reporting proxy vote results.
- personJerry McLaughlin
Elected Class III director.
